Maximilian Konig is a Rheumatology/Immunology physician affiliated with Howard Hughes Medical Institute. OpenAlex indexes 121 publications with 4,013 citations (h-index 32).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1800 Orleans St
Baltimore, MD 21287
Telephone
410-955-5000Provider last certified this registry record 7 Jul 2021.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Legend Biotech USA Inc.Program year20258 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Alexion Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
59.4%Antimalarial59.4%Hydroxychloroquine Sulfate100%Part D<11 patientsCancer & immunology
40.6%Folate Analog Metabolic Inhibitor40.6%Methotrexate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2024 per NIH RePORTER. The latest:
- Precision immunotherapies targeting the 9G4 idiotype in lupus erythematosus
Johns Hopkins University
FY2024$204,688R21AI176764 - Precision immunotherapies targeting the 9G4 idiotype in lupus erythematosus
Johns Hopkins University
FY2023$245,625R21AI176764
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis
The Lancet Rheumatology
2024 - Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
Journal of Clinical Investigation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”